Forest plot for TNF- by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Depletion of viral UL87 LTF in late infection does not affect viral long promoter transcription. by Qiaolin Hu (8677473)

“…<b>(B)</b> UCSC Genome Browser of the MIE promoter/enhancer and downstream region show that dTag degrader treatment significantly decreased transcription from the LTF-dependent UL124 promoter and enhancer promoter EP2 (gold arrowheads). …”

Bias risk assessment of included studies. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for hs-CRP. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for IL-6. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The timeline of the experiment. by Shadi Nazarizadeh (20108029)

“…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …”

S1 Raw data - by Shadi Nazarizadeh (20108029)

“…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …”

S1 Graphical abstract - by Shadi Nazarizadeh (20108029)

“…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …”

(A) Predicted probabilities of snails at or above the water line across different fish species chemical cues. by Alexandra Sack (4805601)

Navigation error analysis. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. …”

Summary of related works. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. …”

Research methodology flow diagram. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. …”